» Articles » PMID: 35528852

Successful Treatment of Linezolid-induced Severe Lactic Acidosis with Continuous Venovenous Hemodiafiltration: A Case Report

Overview
Journal Saudi Pharm J
Specialty Pharmacy
Date 2022 May 9
PMID 35528852
Authors
Affiliations
Soon will be listed here.
Abstract

Linezolid is an oxazolidinone antibiotic. Linezolid-associated lactic acidosis has been reported in 6.8% of linezolid-treated patients. Lactic acidosis is associated with poor clinical outcomes, with high blood lactate levels resulting in organ dysfunction and mortality. This case report describes the development of lactic acidosis in a 64-year-old Chinese woman who had received 33 days of treatment with antituberculosis drugs and 28 days of treatment with oral linezolid for tuberculous meningitis. Severe lactic acidosis was reversed by withdrawing antituberculosis drugs and using continuous venovenous hemodiafiltration (CVVH). When the patient's condition was stable, she was transferred to the infectious disease department, and antituberculosis drugs, with the exception of linezolid, were reintroduced. This did not result in recurrence of lactic acidosis. The causal relationship between lactic acidosis and linezolid was categorized as 'probable' on the Adverse Drug Reaction Probability Scale. This case demonstrates that CVVH has potential as an alternative to discontinuation of linezolid alone for rapid reversal of linezolid-associated severe lactic acidosis.

References
1.
Matsumoto K, Shigemi A, Takeshita A, Watanabe E, Yokoyama Y, Ikawa K . Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients. Int J Antimicrob Agents. 2014; 44(3):242-7. DOI: 10.1016/j.ijantimicag.2014.05.010. View

2.
Cattaneo D, Gervasoni C, Cozzi V, Castoldi S, Baldelli S, Clementi E . Therapeutic drug management of linezolid: a missed opportunity for clinicians?. Int J Antimicrob Agents. 2016; 48(6):728-731. DOI: 10.1016/j.ijantimicag.2016.08.023. View

3.
Pannu N, Gibney R . Renal replacement therapy in the intensive care unit. Ther Clin Risk Manag. 2008; 1(2):141-50. PMC: 1661614. DOI: 10.2147/tcrm.1.2.141.62908. View

4.
Koh W, Kwon O, Gwak H, Chung J, Cho S, Kim W . Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J Antimicrob Chemother. 2009; 64(2):388-91. DOI: 10.1093/jac/dkp171. View

5.
Thibault C, Kassir N, Goyer I, Theoret Y, Litalien C, Moussa A . Population Pharmacokinetics of Intravenous Linezolid in Premature Infants. Pediatr Infect Dis J. 2018; 38(1):82-88. DOI: 10.1097/INF.0000000000002067. View